Cantharidin
As of the edition of 20 October 2026, Cantharidin is a small molecule: marketed, first approved in 1984 (CA); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Ycanth
- First approved
- 31 December 1984 (CA)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Torii Pharmaceutical Co., Ltd.; 3 holders in all
- Registered trials
- 10, 1 stopped early
- Disease areas
- Skin and connective tissue; Infections; Bones, joints and muscles; Immune system; Urinary and reproductive
US protection
US protection ends in 2028.
The last listed US exclusivity ends in 2028. The application that gives this date is held by Verrica Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 6 | 4 | 1 | 1 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Verrica Pharmaceuticals | Applicant | 2023 to now |